Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Interest Expenses (2016 - 2022)

PharmaCyte Biotech (PMCB) has disclosed Interest Expenses for 11 consecutive years, with $3906.0 as the latest value for Q3 2022.

  • Quarterly Interest Expenses rose 144.12% to $3906.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $3906.0 through Apr 2023, up 137.88% year-over-year, with the annual reading at $509.0 for FY2022, 57.15% down from the prior year.
  • Interest Expenses for Q3 2022 was $3906.0 at PharmaCyte Biotech, up from $42.0 in the prior quarter.
  • The five-year high for Interest Expenses was $3906.0 in Q3 2022, with the low at $42.0 in Q4 2021.
  • Average Interest Expenses over 3 years is $1045.0, with a median of $453.0 recorded in 2020.
  • Peak annual rise in Interest Expenses hit 312.37% in 2021, while the deepest fall reached 93.8% in 2021.
  • Over 3 years, Interest Expenses stood at $677.0 in 2020, then crashed by 93.8% to $42.0 in 2021, then soared by 9200.0% to $3906.0 in 2022.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $3906.0, $42.0, and $1600.0 for Q3 2022, Q4 2021, and Q3 2021 respectively.